Harnessing Biomarkers & Molecular Profiling in Ovarian Cancer Treatment

A medical professional examines the pivotal roles of molecular profiling, next-generation sequencing, and germline testing in guiding treatment decisions for ovarian cancer.

EP: 1.NCCN Guidelines Update Adds Mirvetuximab Soravtansine Plus Bevacizumab for FRα-Expressing, Platinum-Sensitive Ovarian Cancer

EP: 2.NCCN Guidelines: Implementing New Therapy Options for Ovarian Cancer

EP: 3.Exploring Therapies for Platinum Sensitive & Platinum-Resistant Ovarian Cancer

EP: 4.MIRASOL trial and DESTINY-PanTumor02 Trial Overview

EP: 5.Tailored Therapy: Decision Making for Ovarian Cancer Treatment

Now Viewing

EP: 6.Harnessing Biomarkers & Molecular Profiling in Ovarian Cancer Treatment

EP: 7.Closing Thoughts on the Current Ovarian Cancer Treatment Landscape

Related Videos

Related Content

Advertisement

April 18th 2025

5 Notable FDA Approvals From March Highlight Advancements Across Therapeutic Areas

Brooke McCormick

From Crohn disease to uncomplicated urinary tract infections and beyond, the FDA issued several high-impact drug approvals last month.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

April 17th 2025

Early Adjuvant Immunotherapy Discontinuation Does Not Affect Melanoma Recurrence Risk

Jared Kaltwasser

Recurrence-free survival rates were similar, even when patients quit adjuvant immunotherapy early, according to a new report.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

April 15th 2025

Elevated Inflammatory Marker Levels Associated With Increased Overactive Bladder Risk

Brooke McCormick

Systemic immune inflammation index, neutrophil-to-lymphocyte ratio, and systemic inflammation response index levels may offer a noninvasive method to identify individuals at increased risk of developing overactive bladder.

April 15th 2025

EHR-Based Symptom Inventory Shows Potential for Ovarian Cancer Monitoring

Brooke McCormick

The electronic health record (EHR)–based symptom inventory identified symptom prevalence and associated comorbidities, but no ovarian cancers were diagnosed during the study period.

Related Content

Advertisement

April 18th 2025

5 Notable FDA Approvals From March Highlight Advancements Across Therapeutic Areas

Brooke McCormick

From Crohn disease to uncomplicated urinary tract infections and beyond, the FDA issued several high-impact drug approvals last month.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

April 17th 2025

Early Adjuvant Immunotherapy Discontinuation Does Not Affect Melanoma Recurrence Risk

Jared Kaltwasser

Recurrence-free survival rates were similar, even when patients quit adjuvant immunotherapy early, according to a new report.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

April 15th 2025

Elevated Inflammatory Marker Levels Associated With Increased Overactive Bladder Risk

Brooke McCormick

Systemic immune inflammation index, neutrophil-to-lymphocyte ratio, and systemic inflammation response index levels may offer a noninvasive method to identify individuals at increased risk of developing overactive bladder.

April 15th 2025

EHR-Based Symptom Inventory Shows Potential for Ovarian Cancer Monitoring

Brooke McCormick

The electronic health record (EHR)–based symptom inventory identified symptom prevalence and associated comorbidities, but no ovarian cancers were diagnosed during the study period.